Remission of the disease associated/related with immunoglobulin IgG4 accompanied by multiple lymphadenopathy after treatment with rituximab and dexamethasone: a case report

Česká verzia

Authors: Zdeněk Adam ¹; Zita Chovancová ²; Markéta Nová ³; Pavel Fabian ⁴; Zdeněk Řehák ^5,6; Renata Koukalová ⁵; Marek Slávik ⁷; Luděk Pour ¹; Marta Krejčí ¹; Aleš Čermák ⁸; Zdeněk Král ¹; Jiří Mayer ¹
Authors place of work: Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice ¹; Ústav klinické imunologie a alergologie LF MU a FN u sv. Anny v Brně ²; Fingerlandův ústav patologie LF UK a FN Hradec Králové ³; Oddělení patologie MOÚ, Brno ⁴; Oddělení nukleární medicíny MOÚ, Brno ⁵; Regionální centrum aplikované molekulární onkologie (RECAMO) MOÚ, Brno ⁶; Klinika radiační onkologie LF MU a MOÚ, Brno ⁷; Urologická klinika LF MU a FN Brno, pracoviště Bohunice ⁸
Published in the journal: Vnitř Lék 2018; 64(3): 290-299
Category: Case Reports

Summary

A disease associated with immunoglobulin IgG4 is a rare unit with very variable symptoms. We describe the course and treatment of the disease in a patient who presented with multiple lymphadenopathy and infiltrates in the area of the retroperitoneum and pelvis and signs of chronic sclerosing pancreatitis. The disease was clinically manifested by a significant loss of weight, but also by a loss of perception of taste and smell. The diagnosis was made based on a high amount of IgG4 expressing plasma cells in the sampled tissue and an increased concentration of immunoglobulins of type IgG and mainly subclass IG4. Rituximab in 475 mg/m2 dose was used in the treatment, the initial four doses of rituximab were administered at 14-day intervals, always with a one-off administration of a 40 mg dose of dexamethasone. According to FDG-PET/CT, only partial remission of the disease was reached after 4 applications of rituximab and dexamethasone. The patient recovered its sense of smell and taste. In another 4 cycles rituximab was administered on day 1 of a 28-day cycle. On days 1 and 15 of the cycle dexamethasone at 40 mg and cyclophosphamide at 600 mg were administered by intravenous infusion. After the completion of 8 cycles of treatment based on rituximab and dexamethasone and with cyclophosphamide added in the second half of the treatment, the control FDG-PET/CT examination proved the complete remission. Before the treatment commencement the concentration of the subclass of immunoglobulin IgG4 was equal to 51.0 g/l, after the completion of the aforementioned treatment it dropped to 3.5 g/l. The patient tolerated the treatment without any adverse effects. Rituximab, dexamethasone and cyclophosphamide induced the complete remission of this disease.

Key words:
IgG4-associated/releated disease – rituximab

Zdroje

1. Blaho M, Dítě P, Bojková M et al. Příspěvek k diferenciální diagnostic sklerozující cholangitidy. Vnitř Lék 2017; 63(1): 50–55.

2. Hrnčíř Z, Laco J. Klinický význam IgG-4 asociované nemoci (IgG4 related disease). Čas Lék Česk 2011; 150(8): 438–441.

3. Laco J. IgG4-asociovaná systemová skleróza: Přehled. Česk Patol 2010; 46(4): 82–85.

4. Honsová E, Lodererová A, Kostolná E et al. Autoimunitní pancreatidass postižením biliárních cest a jater jako součást IgG4-asociované autoimunitní sklerozující choroby (IgG4 related autoimmune sclerosing disease). Česk Patol 2010; 46(3): 65–67.

5. Matěj R. Monitor aneb nemělo by vám uniknout, že Wegenerova granulomatóza, co již není Wegenerova granulomatóza, může mít vztah k systémovému onemocnění asociovanému s IgG4. Česk Patol Soud Lék 2014; 50–59(4): 60.

6. Matěj R. Monitor aneb nemělo by vám uniknout, že plicní hyalinizující granulom je možná formou systémového skerózujícího onemocnění asociovaného s IgG4. Česk Patol Soud Lék 2012; 57–48(4): 176.

7. Bojková M, Dítě P, Dvořáčková J. Immunoglobulin G4, autoimmune pancreatitis and pancreatic cancer. Digestive Diseases 2015; 33(1): 86–90. Dostupné z DOI: <http://dx.doi.org/10.1159/000368337>.

8. Danningerová-Molnárová A. Autoimunitná pankreatitída. Interná medicína 2012; 12(4): 172–176.

9. Dítě P, Husová L, Lukás Z et al. Immunoglobulin IG4-asociovaná cholangitida. Vnitř Lék 2010; 56(8): 824–826.

10. Dítě P, Novotný I, Kianička P. Imunologlobulin IgG4 associovaná onemocnění. Gastroenterológia pre prax 2011; 10(3): 151–152.

11. Dítě P, Novotný I, Kinkor Z et al. Autoimunní forma chronické pankreatitidy a IgG4 pozitivní mastitida. Gastroent Hepatol 2011; 65(1): 22–25.

12. Dítě P, Novotný I, Lata J et al. Autoimunitní pankreatitida a IgG4 pozitivní sklerotizující cholangitida Vnitřní Lék 2011; 57(3): 254–257.

13. Drahoš J, Vyhnálek P. Imunoglobulin G4 asociovaná sklerozující cholangitida u pacienta s Crohnovou nemocí. Gastroenterol Hepatol 2017; 71(1): 49–52.

14. Hrnčíř Z, Laco J, Slezák R et al. Mikuliczova choroba s jednostranným exoftalmem – onemocnění se vztahem k IgG4. Česká Revmatol 2011; 19(3): 125–130.

15. Hybášková J, Zeleník K, Urban O Manifestace IgG4 asociované nemoci v oblasti hlavy a krku. Otorinolaryng Foniat 2015; 64(3): 163–167.

16. Laco J, Podhola M, Kamarádová K et al. Idiopathic vs. secondary retroperitoneal fibrosis: a clinicopathological study of 12 cases, with emphasis to possible relationship to IgG4-related disease. Virchows Archiv 2013; 463(5): 721–730. Dostupné z DOI: <http://dx.doi.org/10.1007/s00428–013–1480–7>.

17. Laco J, Örhalmi J, Bártová J et al. Enterocolic lymphocytic phlebitis as a newly recognized manifestation of IgG4-related disease Intern J Surg Pathol 2015; 23(2): 165–169. Dostupné z DOI: <http://dx.doi.org/10.1177/1066896914539549>.

18. Laco J. Monitor aneb nemělo by vám uniknout, že IgG4 choroba se může v oblasti hlavy a krku manifestovat jako tumoriformní slizniční léze. Česk Patol Soud Lék 2013; 49–58(4): 111.

19. Laco J. Systémová sklerozující choroba spojená s imunoglobuliny IgG4 – současné poznatky. Česk Patol Soud Lék 2010; 46–55(4): 82–85.

20. Losse S, Žurková M. Plicní projevy nemoci asociované s IgG4. Postgrad Med 2017; 19: 120–128.

21. Merta M. Klinický obraz onemocnění ledvin asociovaných s IgG4. Postgrad Nefrol 2013; 11(2): 26–27.

22. Mikulová Š, Jílek D, Richter J. Nemoc asociovaná s IgG4. Úvod, patogeneze, diagnostika. !. část. Alergie 2015; 17(1): 16–24.

23. Mikulová Š, Jílek D, Richter J. Nemoc asociovaná s IgG4. Klinický obraz, orgánová postižení a terapie. 2. část. Alergie 2015; 17(2): 91–99.

24. Novotný I, Dítě P, Trna J. Immunoglobulin G4-related cholangitis: a variant of IgG4-releated systemic disease. Dig Dis 2012; 30(2): 216–219. Dostupné z DOI: <http://dx.doi.org/10.1159/000336706>.

25. Průcha M, Sedláčková L. Onemocnění asociovaná s IgG4 – pacient s mnohočetným orgánovým postižením. Medicína po promoci 2016; 17(1): 70–71.

26. Dítě P, Novotný I, Kala Z et al. Pozitivita imunoglobulinu IgG4 v krevním séru u osob s karcinomem slinivky břišní. Gastroent Hepatol 2012; 66(3): 187–190.

27. Průcha M, Czinner R. IgG4-related diseases – a rare polycystic form of Ormond‘s disease. Prague Med Rep 2016; 117(2–3): 124–128.

28. Šteiner I, Laco J. IgG4-related disease of the aortic valve. Cardiovasc Pathol 2015; 24(4): 264. Dostupné z DOI: <https://doi.org/10.1016/j.carpath.2015.04.003>.

29. Vaňásek J, Hoffmann P, Laco J et al. IgG4 asociovaná pankreatitida a cholangoitida. Čes Radiol 2014; 68(4): 294–297.

30. Mikulicz J. Über eine eigenartige symmetrishe erkrankung der Tranen und Mundspeicheldrüsen. Beitr Chir Festschr Theodor Billroth 1892: 610–630.

31. Hamano H, Kawa S, Horiuchi A et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001; 344(10): 732–788. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200103083441005>.

32. Sarles H, Sarles JC, Muratore R et al. Chronic inflammatory sclerosis of the pancreas – an autonomous pancreatic disease? Am J Dig Dis 1961; 6: 688–698.

33. Umehara H, Okazaki K, Masaki Y et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 2012; 22(1): 1–14. Dostupné z DOI: <http://dx.doi.org/10.1007/s10165–011–0508–6>.

34. Stone JH, Khosroshahi A, Deshpande V et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 2012; 64(10): 3061–3067. Dostupné z DOI: <http://dx.doi.org/10.1002/art.34593>.

35. Khosroshahi A, Wallace ZS, Crowe JL et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015; 67(7): 1688–1699. Dostupné z DOI: <http://dx.doi.org/10.1002/art.39132>.

36. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366(6): 539–551. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra1104650>.

37. Kleger A, Seufferlein T, Wagner M et al. IgG4-related autoimmune diseases: polymorphous presentation complicates diagnosis and treatment. Dtsch Arztebl Int 2015; 112(8): 128–135. Dostupné z DOI: <http://dx.doi.org/10.3238/arztebl.2015.0128>.

38. Nirula A, Glaser SM, Kalled SL et al. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 2011; 23(1): 119–124. Dostupné z DOI: <http://dx.doi.org/10.1097/BOR.0b013e3283412fd4>. Erratum in Curr Opin Rheumatol 2011; 23(2): 227. Taylora, Frederick R [corrected to Taylor, Frederick R].

39. Okazaki K, Umehara H. Are classification criteria for IgG4-RD now possible? The concept of IgG4-related disease and proposal of comprehensive diagnostic criteria in Japan. Int J Rheumatol 2012; 2012: 357071. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/357071>.

40. Chen Y, Zhao J, Feng R et al. Types of Organ Involvement in Patients with Immunoglobulin G4-related Disease. Chin Med J (Engl) 2016; 129(13): 1525–1532. Dostupné z DOI: <http://dx.doi.org/10.4103/0366–6999.184459>.

41. Fernández-Codina A, Martínez-Valle F, Pinilla B et al. IgG4-Related Disease: Results From a Multicenter Spanish Registry. Medicine (Baltimore) 2015; 94(32): e1275. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000001275>.

42. Inoue D, Yoshida K, Yoneda N et al. IgG4-related disease: dataset of 235 consecutive patients. Medicine (Baltimore) 2015; 94(15): e680. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000000680>.

43. Kanno A, Masamune A, Okazaki K et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2011. Pancreas 2015; 44(4): 535–539. Dostupné z DOI: <http://dx.doi.org/10.1097/MPA.0000000000000325>.

44. Yadav D, Notahara K, Smyrk TC et al. Idiopathic tumefactive chronic pancreatitis: clinical profile, histology, and natural history after resection. Clin Gastroenterol Hepatol 2003; 1(2): 129–135. Dostupné z DOI: <http://dx.doi.org/10.1053/cgh.2003.50016>.

45. Kamisawa T, Zen Y, Pillai S et al. IgG4-related disease. Lancet 2015; 385(9976): 1460–1471. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(14)60720–0>.

46. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366(6): 539–551. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra1104650>.

47. Carruthers MN, Khosroshahi A, Augustin T et al. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 2015; 74(1): 14–18. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2013–204907>.

48. al Zahrani H, Kyoung KT, Khalili K et al. IgG4-related disease in the abdomen: a great mimicker. Semin Ultrasound CT MR 2014; 35(3): 240–254. Dostupné z DOI: <http://dx.doi.org/10.1053/j.sult.2013.12.002>.

49. Shimosegawa T, Chari ST, Frulloni L et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the international association of pancreatology. Pancreas 2011; 40(3): 352–358. Dostupné z DOI: <http://dx.doi.org/10.1097/MPA.0b013e3182142fd2>.

50. Ohara H, Okazaki K, Tsubouchi H et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci 2012; 19(5): 536–542. Dostupné z DOI: <http://dx.doi.org/10.1007/s00534–012–0521-y>.

51. Masaki Y, Sugai S, Umehara H. IgG4-related diseases including Mikulicz’s disease and sclerosing pancreatitis: diagnostic insights. J Rheumatol 2010; 37(7): 1380–1385. Dostupné z DOI: <http://dx.doi.org/10.3899/jrheum.091153>.

52. Kawano M, Saeki T, Nakashima H et al. Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol 2011 15(5): 615–626. Dostupné z DOI: <http://dx.doi.org/10.1007/s10157–011–0521–2>.

53. Kamisawa T, Chari ST, Giday SA et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas 2011; 40(6): 809–814. Dostupné z DOI: <http://dx.doi.org/10.1097/MPA.0b013e3182258a15>.

54. Maillette De Buy, Wenniger LJ, Doorenspleet ME et al. Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology 2013; 57(6): 2390–2398. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.26232>.

55. Wallace ZS, Mattoo H, Carruthers M et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 2015; 74(1): 190–195. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2014–205233>.

56. Hart PA, Topazian MD, Witzig TE et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013; 62(11): 1607–1615. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2012–302886>.

57. Gu WJ, Zhang Q, Zhu J et al. Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation: A case report and literature review. Medicine (Baltimore) 2017; 96(24): e6934. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000006934>.

58. Mochizuki H, Kato M, Higuchi T et al. Overlap of IgG4-related Disease and Multicentric Castleman‘s Disease in a Patient with Skin Lesions. Intern Med 2017; 56(9): 1095–1099. Dostupné z DOI: <http://dx.doi.org/10.2169/internalmedicine.56.8013>.

59. Aouidad I, Schneider P, Zmuda M et al. IgG4-Related Disease With Orbital Pseudotumors Treated With Rituximab Combined With Palpebral Surgery. JAMA Dermatol 2017; 153(3): 355–356. Dostupné z DOI: <http://dx.doi.org/10.1001/jamadermatol.2016.4854>.

60. Wallace ZS, Mattoo H, Mahajan VS et al. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford) 2016; 55(6): 1000–1008. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/kev438>.

61. Carruthers MN, Topazian MD, Khosroshahi A et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015; 74(6): 1171–1177. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2014–206605>.

62. Berta AI, Agaimy A, Braun JM et al. Bilateral Orbital IgG4-Related Disease with Systemic and Corneal Involvement Showing an Excellent Response to Steroid and Rituximab Therapy: Report of a Case with 11 Years Follow-Up. Orbit 2015; 34(5): 299–301. Dostupné z DOI: <http://dx.doi.org/10.3109/01676830.2015.1057290>.

63. McMahon BA, Novick T, Scheel PJ et al. Rituximab for the Treatment of IgG4-Related Tubulointerstitial Nephritis: Case Report and Review of the Literature. Medicine (Baltimore) 2015; 94(32): e1366. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000001366>.

64. Gillispie MC, Thomas RD, Hennon TR. Successful treatment of IgG-4 related sclerosing disease with rituximab: a novel case report. Clin Exp Rheumatol 2015; 33(4): 549–550.

65. Yamamoto M, Awakawa T, Takahashi H. Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years. Ann Rheum Dis 2015; 74(8): e46. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2015–207625>.

66. Wu A, Andrew NH, Tsirbas A et al. Rituximab for the treatment of IgG4-related orbital disease: experience from five cases. Eye (Lond) 2015; 29(1): 122–128. Dostupné z DOI: <http://dx.doi.org/10.1038/eye.2014.251>.

67. Savino G, Battendieri R, Siniscalco A et al. Intraorbital injection of Rituximab in idiopathic orbital inflammatory syndrome: case reports. Rheumatol Int 2015; 35(1): 183–188. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296–014–3054–7>.

68. Chen TS, Figueira E, Lau OC et al. Successful “medical” orbital decompression with adjunctive rituximab for severe visual loss in IgG4-related orbital inflammatory disease with orbital myositis. Ophthal Plast Reconstr Surg 2014; 30(5): e122-e125. Dostupné z DOI: <http://dx.doi.org/10.1097/IOP.0b013e3182a64fa4>.

69. Jalilian C, Prince HM, McCormack C et al. IgG4-related disease with cutaneous manifestations treated with rituximab: case report and literature review. Australas J Dermatol 2014; 55(2): 132–136. Dostupné z DOI: <http://dx.doi.org/10.1111/ajd.12100>.

70. Caso F, Fiocco U, Costa L et al. Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis. Joint Bone Spine 2014; 81(2): 190–192. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbspin.2013.07.011>.

71. Ebbo M, Grados A, Guedj E et al. Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study. Arthritis Care Res (Hoboken) 2014; 66(1): 86–96. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.22058>.

72. Shinoda K, Taki H, Sugiyama T et al. Recurrence of IgG4-related disease following treatment with rituximab. Mod Rheumatol 2013; 23(6): 1226–1230. Dostupné z DOI: <http://dx.doi.org/10.1007/s10165–012–0738–2>.

73. Khosroshahi A, Carruthers MN, Deshpande V et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 2012; 91(1): 57–66. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0b013e3182431ef6>.

74. Khosroshahi A, Bloch DB, Deshpande V et al. JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62(6): 1755–1762. Dostupné z DOI: <http://dx.doi.org/10.1002/art.27435>.

75. Kashiwagi N, Enoki E, Hosokawa C et al. 18F-FDG PET/CT Features of Chronic Sclerosing Sialadenitis Presenting as Localized IgG4-Related Disease. Clin Nucl Med 2017; 42(2): 131–132. Dostupné z DOI: <http://dx.doi.org/10.1097/RLU.0000000000001482>.

76. Fu Z, Liu M, Zhang J et al. IgG4-Related Renal Lesions Detected by Delayed 18F-FDG PET/CT Scan. Clin Nucl Med 2017; 42(1): 66–67. Dostupné z DOI: <http://dx.doi.org/10.1097/RLU.0000000000001427>.

77. Ichiki A, Hashimoto N, Ueda T et al. IgG4-related Disease with Bone Marrow Involvement. Intern Med 2016; 55(16): 2295–2299. Dostupné z DOI: <http://dx.doi.org/10.2169/internalmedicine.55.6749>.

78. Lee J, Hyun SH, Kim S et al. Utility of FDG PET/CT for Differential Diagnosis of Patients Clinically Suspected of IgG4-Related Disease. Clin Nucl Med 2016; 41(5): e237-e243. Dostupné z DOI: <http://dx.doi.org/10.1097/RLU.0000000000001153>.

79. Zhao Z, Wang Y, Guan Z et al. Utility of FDG-PET/CT in the diagnosis of IgG4-related diseases. Clin Exp Rheumatol 2016; 34(1): 119–125.

80. Lauwyck J, Piette Y, Van Walleghem L et al. IgG4-related disease: The utility of (18)F-FDG PET/CT in diagnosis and treatment. Hell J Nucl Med 2015; 18(Suppl 1): 155–159.

81. Zhang J, Chen H, Ma Y et al. Characterizing IgG4-related disease with ¹F-DG PET/CT: a prospective cohort study. Eur J Nucl Med Mol Imaging 2014; 41(8): 1624–1634. Dostupné z DOI: <http://dx.doi.org/10.1007/s00259–014–2729–3>.

82. Kase S, Ishijima K, Uraki T et al. Usefulness of Flow Cytometry in Diagnosis of IgG4-Related Ophthalmic Disease and Extranodal Marginal Zone B-Cell Lymphoma of the Ocular Adnexa. Anticancer Res 2017; 37(9): 5001–5004. Dostupné z DOI: <http://dx.doi.org/10.21873/anticanres.11913>.

83. Lin W, Zhang P, Chen H et al. Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease. Arthritis Res Ther 2017; 19(1): 25. Dostupné z DOI: <http://dx.doi.org/10.1186/s13075–017–1231–2>.

84. Wallace ZS, Deshpande V, Mattoo H et al. IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients. Arthritis Rheumatol 2015; 67(9): 2466–2475. Dostupné z DOI: <http://dx.doi.org/10.1002/art.39205>.